Published in final edited form as:

AIDS Rev. 2019 ; 21(2): 76–83. doi:10.24875/AIDSRev.19000051.

Differential Contribution of HIV-1 Subtypes B and C to Neurological Disorders: Mechanisms and Possible Treatments

Maryline Santerre^{1,§}, Ying Wang^{1,§}, Sterling Arjona¹, Charles Allen¹, Bassel E. Sawaya²

¹Molecular Studies of Neurodegenerative Diseases Lab, FELS Institute for Cancer Research and Molecular Biology;

²Department of Neurology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.

Abstract

With the introduction of combinatory antiretroviral therapy, patients infected with human immunodeficiency virus type 1 (HIV-1) can live much longer than before. However, the identification of HIV-associated neurocognitive disorder (HAND), especially HIV-associated dementia in 15–20% of patients infected with HIV-1, indicates additional complexity. These disorders turn out to be subtype dependent. Recently, many studies are ongoing trying to understand how the virus induces neuronal injury which could lead to neurological dysfunction. Most of these studies are focusing on the HIV-1 release of proteins such as Tat. However, the exact role of these proteins and their involvement in neuronal degeneration remains unidentified; this is especially true since viral proteins from different HIV-1 subtypes differ in their ability to cause neuronal damage. This review describes the role of different HIV-1 subtypes, identifies probable pathways involved in neuronal damage, the contribution of different HIV-1 subtypes to the progression of HAND, and potential treatments for HAND.

Keywords

HIV-1; Subtypes; HIV-associated neurocognitive disorder

Introduction

Patients infected with human immunodeficiency virus type 1 (HIV-1) (35.1 million adults and 1.8 million children [<https://www.WHO.int/hiv/data/en/>]) including those using the effective but not curative combinatory antiretroviral therapy (cART) suffer from deregulation and impairment of organs such as heart, kidney, and brain¹. Studies involving 37,000 HIV-infected patients using cART (from 2003 to 2013) showed that comorbidity increased with age in those patients compared to uninfected patients and having the same age². AIDS-

Correspondence to: Bassel E. Sawaya, Fels Institute for Cancer Research, Lewis Katz School of Medicine, Temple University, 3307 North Broad Street; Philadelphia, Pennsylvania 19140, sawaya@temple.edu.

[§]Equal Contribution

Conflicts of interest
None.

related deaths have been reduced by 51% since 2004 (the peak of HIV-related deaths) and have further decreased from 1.4 million in 2010 (<https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics>).

HIV is divided into two types, HIV-1 and HIV-2, among which HIV-1 is the most common. HIV-1 is further separated into three groups: major Group M (major), non-major Group N (non-M, non-O), and Group O (outlier). By far, more than 90% of AIDS cases derive from the infection of HIV-1 Group M (https://www.avert.org/professionals/hiv-science/types-strains#footnote1_g11pyu4 and References within). Group M is divided into subtypes (clades), among these are the most studied subtypes: A, B, C, and D. Subtype C is the most prevalent subtype in Asia, while subtypes A and D are found mainly in Africa. Subtype B is the predominant type in the developed world, including the United States and European countries. Some of the subtypes are described to be more virulent or more resistant to different drugs³. Epidemiological research found that disease progression is closely related to the different viral subtypes⁴. Furthermore, the progression and severity of HIV-associated neurocognitive disorder (HAND), which is common in patients even in the cART era, is found to be different in patients infected with different HIV-1 subtypes. This review will discuss the role of these subtypes and their contribution in the progression of HAND.

Impact of HIV-1 subtypes on the progression of neurological disorders

Approximately 30–50% of HIV-infected patients develop some neurological dysfunction, ranging from mild-to-severe symptoms. HAND is now classified into three categories: minor cognitive/motor disorder (impairment in more than one cognitive abilities); mild cognitive/motor complex (CMC) (cognitive abnormality with mild functional disorder), and HIV-associated dementia (HAD). HAD is the most severe HAND identified by severe functional impairment resulting in dramatic reductions in the ability to care for oneself, work efficiency, and quality of life.

HAND symptoms result from neuronal deregulation directly or indirectly brought on by HIV-1 infection in the central nervous systems (CNS). HIV does not infect neurons; however, HIV-1 does infect microglia and brain-resident macrophages. These infected cells produce and release toxic diffusible factors that can lead to neuronal death (Fig. 1). In addition to exerting a toxic effect on neurons through macrophages and microglia, HIV viral proteins are found to cause neuronal dysfunction and neuronal death in recent studies. Tat, one of the six regulatory viral proteins controlling the ability of HIV to infect cells, is detectable in the serum of HAND patients. TAT protein and mRNA levels correlate with the severity of neurological dysfunction^{5,6}. In PSAPP mice, Tat expression in astrocytes induced neurodegeneration, tau phosphorylation, and amyloid deposition in the brain – confirming the neurotoxicity of Tat⁷. Tat enters neurons by receptor-mediated endocytosis and directly induces apoptosis in both rat and human neurons. This apoptosis is caused by the expression of AMPAR through the release of tumor necrosis factor- α independent of nuclear factor κ B activation⁸. Further studies found that nitric oxide synthase and endolysosomes are also involved in Tat-induced neurotoxicity^{9,10}. Synapse loss brought on by HIV Tat is dependent on calcium influx through N-methyl-D-aspartate receptor (NMDAR) and the activity of mir-128a, which inhibits the expression of the presynaptic protein SNAP25¹¹.

In addition to Tat, Vpr, a second regulatory viral protein presents in the serum and cerebrospinal fluid (CSF) of HIV patients, causes a depolarization of neurons. Vpr causes an inward current by forming cation-selective ion channels across the cytoplasmic membrane, resulting in hippocampal neuronal death¹². The first 40 N-terminal amino acids of Vpr are sufficient to create the ion channel which results in neuron death¹³. Besides the ability of the N-terminal region to induce neuronal death, the C-terminal fragment (70–96) is also found to cause neuronal apoptosis associated with the activation of caspase-3¹⁴. Similarly, caspase-8 activation is identified in human neuronal cultures after exposure to Vpr¹⁵. In *in vivo* studies done in neonatal mice, Vpr is injected through the ventricle and induces the loss of neurons and dendritic processes in the cortex, hippocampus, cerebellum, and choroids plexus¹⁶. Transgenic mice expressing Vpr in basal ganglia monocytoic cells exhibit behavior deficits. Neuronal injury is also observed in the basal ganglia of these mice, including the activation of caspase-3 as well as loss of synaptophysin, GABAergic, and cholinergic neurons¹⁷.

Gp120, a glycoprotein that forms part of the HIV-1 envelope, interacts with several receptors found in the CNS such as CD4, CCR5, CXCR4, and nAChR^{18–20}. Gp120 kills neurons by stimulating the neurotoxic pathways mediated by nitric oxide, calcium, glutamate, and superoxide anions^{21,22}. Besides these classical neurotoxic pathways, gp120 reduces intracellular furin levels reducing the cleavage of pro-brain-derived neurotrophic factor (BDNF) into mature BDNF. This reduction in cleavage results in the imbalance between antiapoptotic and proapoptotic neurotrophins, contributing to neuronal injury²³. Cell death brought by gp120IIIB found in subtype B HIV-1, has a specificity for the CXCR4 receptor, and could also be mediated by the calcium – highly permeable acetylcholine receptor $\alpha 7$ -nAChR. The expression of $\alpha 7$ -nAChR increases in gp120-treated SH-SY5Y cells and gp120-transgenic mice striatum²⁴. The gp120IIIB-induced neurotoxicity in neurons requires the presence of CXCR4, phosphatase, and tensin homolog on chromosome 10 (PTEN) and p38 MAPK^{25–28}.

Until now, it is a common belief that HIV-1 virus can-not infect neurons but does infect brain macrophages. However, the HIV-Nef gene sequence was detected in hippocampal neurons isolated from postmortem HIV patients²⁹. These findings corroborate with other reports that used *in situ* PCR and demonstrated the presence of viral proteins in neurons³⁰, suggesting the possibility that HIV-1 can infect neurons. If indeed neurons could be infected by the HIV, there would be additional neuronal damage since Nef has been found to bind directly to calmodulin. Calmodulin is involved in a wide range of cellular calcium-dependent signaling pathways by regulating the activity of many enzymes³¹. Furthermore, Nef causes an increase in K⁺ current evoked after membrane depolarization, either by direct binding to the K⁺ channel or through interacting with receptors regulating the K⁺ channel³². The possibility that Nef contributes to the neuronal damage reported in HIV-patients is further supported by human neuronal cultures after exposure to Nef that results in nuclear fragmentation and a decrease in cell number³³. Furthermore, transgenic mice expressing Nef in astrocytes exhibit impaired spatial and recognition memory, supporting the contribution of Nef to HAND³⁴.

There have been several studies conducted to identify the relationship between HIV-1 subtypes, and the severity of neurocognitive impairments with individuals infected by different subtypes of HIV-1. In one of these studies, researchers found that among those HIV-infected adults in Uganda, HAD is more common in patients with subtype D (which is more CXCR4-tropic) than those infected with subtype A (which is more CCR5-tropic). On the other hand, in HIV-infected children with subtype A, they demonstrated no statistical difference than those infected with subtype D³⁵. Besides the relationship of subtypes A and D with the neurocognitive disorder, subtype C is found to have slower replication kinetics in monocyte-derived macrophages, leading to lower levels of macrophage-mediated neurotoxicity³⁶. The diminished neuroinvasive capacity of subtype C is contributed to the different primary conformation of Tat. Tat from subtype C does not cause neuron injury unless morphine was present and acted through glial cells expressing μ -opioid receptors³⁷. Clinically, patients infected with subtype C show decreased incidence of cognitive deficits³⁸. Severe combined immune deficiency mice injected with macrophages infected by subtype B display more severe cognitive deficits than mice infected with subtype C³⁹. *In vitro* studies have found that subtype B Tat is more potent than subtype C Tat when inducing neuronal death (Fig. 2)⁴⁰.

Studies in recent years have discovered subtype-specific differences in the neurotoxicity and the induction of A β production in neurons by HIV-1 Tat protein from subtypes B and C⁴¹. These differences are attributed to the di-cysteine C30–C31 motif found in Tat from subtype B⁴². The mechanism why subtype C Tat protein is less neurotoxic might be attributed to the natural mutation found at cysteine 31 that is critical in mediating persistent excitation of the NMDAR. This persistent excitation is achieved by disrupting a disulfide bond on the NR1 subunit of the NMDAR that eventually leads to cognitive dysfunctions⁴³.

In addition to the lower toxicity of Tat protein from subtype C, gp120 protein from the same subtype was also found to be less toxic compared to that isolated from subtype B. As indicated in the results from human astrocytes, subtype B gp120 induces higher levels of glutamate, as well as prostaglandin E2 and thromboxane A2 receptor, the neuropathogenic byproducts of cyclooxygenase-2-mediated arachidonic acid metabolism⁴⁴. Further, the capability of inducing CMC is hypothesized to be determined by the mutations in the gp120 sequences, which means that there exist some variations of gp120 specific for causing CMC⁴⁵. Speaking of particular mutations in viral proteins responsible for causing cognitive dysfunction, a mutation at amino acid 77 in Vpr distinguishes HIV patients with (77Q) or without (77R) HAND. However, 77Q is dominant in HIV patients with dementia; the Vpr protein with the 77Q mutation is found to induce less neurotoxicity than Vpr with 77R⁴⁶.

Similar conditions apply to Nef, the three-dimensional structure of Nef in the brain of HAD patients infected with HIV-1 subtype B is found to be more identical to Nef from subtype D and less similar to Nef collected from patients that do not have HAD. In addition, Nef from the brain of HAD patients is structurally different from Nef from the same patient's peripheral organs indicating the possible existence of specific genetic alterations that change the structure of Nef in the brain, which contributes to cognitive deficit⁴⁷.

Potential treatments of HAND

At present, there are no specific treatments for HAND. The treatment of HAND usually employs a multidisciplinary approach with neurologists, HIV specialists, psychiatrists, and psychologist participating. Early studies identified reversal of brain metabolic abnormalities⁴⁸ and improvement in motor functions in patients receiving a higher dose of zidovudine (azidothymidine [AZT]), a nucleoside reverse transcriptase inhibitor (NRTI). AZT treatment resulted in lower dementia prevalence^{49–52}, indicating the activity of this antiretroviral drug in preventing HAND. Since AZT generally does not entirely stop HIV replication, only slowing replication down it is usually combined with other antiretroviral drugs. Studies have found that cART was able to reduce the incidence of HAD⁵³ and improve motor speed performance in patients receiving a specific cART combination⁵⁴. However, some antiretroviral agents such as efavirenz (EFV) and rilpivirine (RPV), which fall in the non-NRTI (NNRTI) class, have CNS side effects that exacerbate neurological dysfunction^{55,56}. Therefore, it is essential for physicians to consider the neurological health of HIV patients when choosing the most appropriate cART drug combination⁵⁷.

Protease inhibitors (PIs) are a class of antiretroviral drugs that inhibit the activity of a protease that cleaves nascent proteins for assembly of new virions. Among the series of PIs developed for HIV patients, some were tested for the effect on β -amyloid deposition *in vitro* and *in vivo*, a hallmark of dementia. Atazanavir, ritonavir, and saquinavir (SQV) were found to modestly inhibit A β degradation while lopinavir, nelfinavir (NFV), and ritonavir enhanced secretion of undigested A β after phagocytosis. Lopinavir, NFV, ritonavir, and SQV were found to inhibit A β 40 production from primary human cortical neurons⁵⁸. Indinavir, another HIV PI, alleviated memory deficits induced by celecoxib or streptozotocin by inhibiting brain AChE activity, as well as thiobarbituric acid reactive species levels and restoring reduced glutathione levels⁵⁹. Ritonavir, in addition to slightly inhibiting A β degradation, induces the expression of P-glycoprotein, a blood–brain barrier (BBB) drug transporter, resulting in restricted entry of HIV PIs into the brain, leading to neurological dysfunction⁶⁰. On the contrary, inhibition of P-glycoprotein at the BBB is found to increase the brain distribution of an HIV PI, NFV, supporting P-glycoprotein as a potential target for HAND⁶¹.

Several factors limit the distribution of the drugs to the brain. First, cART can bound the plasma proteins and therefore be less available for the CNS⁶². Second, the BBB has a complex structure which is a major obstacle for an effective drug delivery and creates a poor pharmacokinetic profile⁶³. Different approaches are developed to deliver cART through the barrier, including biotechnologies, prodrugs based, nanogels, liposomes, or chemical modification for CNS delivery⁶⁴.

NRTI has a low molecular weight and low protein binding and therefore reaches a good CSF concentration. Raltegravir (RGV) exhibits a good passage into CSF. Nevirapine (NVP) had the highest CSF/plasma penetration compared to other drugs. In the opposite, the penetrability of EFV in CSF is limited. Moreover, the PIs have, in general, a limited penetrability in the CSF due to the presence of efflux mechanisms and high plasma protein binding. However, their penetrability can be boosted by low-dose ritonavir. Some PIs like

SQV, NFV, tipranavir, and atazanavir do not even reach therapeutical concentrations in CSF and can be were below the detection limit⁶⁵.

The dolutegravir resistance is more common in subtype B versus non-B clades (18.7% vs. 22%), due to a G140S substitution. In all the non-B, two nucleotides are required, raising the genetic barrier to the emergence of G140S mutations⁶⁶. In the RGV population, HIV-1 subtype B develops the mutations N155H, Q148H/R/K, and Y143R/C/H. The mutation Q148H/R/K can be found with 13% of prevalence in all B subtypes versus 0% in non-B. However, some studies showed the same susceptibility among the integrase inhibitors, RGV, elvitegravir, and MK-2408 with HIV-1 subtype B and C, resulting in similar outcomes⁶⁷.

Despite having a low genetic barrier, EFV and NVP have been widely used. A single mutation in the binding pocket of the NNRTIs is sufficient to initiate a clinical failure⁶⁸. The NNRTI resistance is caused by two mechanisms: the mutations K103N and E138K affecting the entry of the NNRTI from the binding pocket^{69,70} or is altering the pocket geometry through the mutations Y181C and Y188L^{71,72}. In tissue culture, under EFV pressure but not NVP or delavirdine, the HIV-1 clade C develops the V160M mutation, conferring high-level resistance to all NNRTIs⁷³. There is no significant difference of V106M prevalence in patients receiving NVP between subtypes B and C⁷⁴. V106M and Y181L are the major NNRTI drug-resistant mutations⁷⁵. The prevalence of V106M is 14% in HIV-infected patients carrying subtype C, whereas a small percentage of subtype B-infected patients carries this mutation⁷⁶.

The prevalence of the other major mutation Y181C is 21% for the subtype B and only 12% for the subtype C, both B and C are likely to develop the Y181C mutation⁷⁷. Some subtype C-infected patients carry mutation such as E138K/Q/R, M230I/L, and Y188L is resistant to etravirine or RPV, respectively, than those infected with subtype B. Moreover, RPV is associated with the E138A substitution occurring more frequently in subtypes C (5.9–7.5%) than B (0–2.3%)⁷⁸.

Besides antiretroviral drugs, other therapies are exhibiting promising effects toward reducing HAND. Memantine and ifenprodil, two GluN2B-preferring NMDAR antagonists, promoted the recovery from Tat-induced synaptic loss and cell survival through inhibiting Tat-induced activation of cell death pathways⁷⁹. Furthermore, estrogen was found to delay Tat-induced neuronal apoptosis by inhibiting a mitochondrial apoptotic signaling pathway in an endoplasmic reticulum-sensitive manner⁸⁰ and decreases the neurotoxicity of factors released by Gp120-treated microglia^{81–83}. Meth-ylphenidate (Ritalin), the psychostimulant employed to alleviate the neuropsychiatric symptoms, was found to improve cognitive performance in patients diagnosed with HAND⁸⁴. A suggested treatment for HAND is to promote the synaptic concentration of dopamine through inhibiting the neurotransmitter transporters involved in the uptake of dopamine in HIV patients with dopaminergic dysfunction^{84–86}.

Another obstacle in reducing HAND is the CNS hosting latent viruses as a reservoir in children and adults, contributing to the virus persistence in the brain. The CNS reservoir might reactivate after cART cessation and spread to other compartments. Some latency-

reversing agents are available but present neurotoxic effects and BBB penetrability issues such as cART⁸⁷.

Conclusion

With the introduction of highly active antiretroviral therapy, the life span of HIV patients has been dramatically prolonged. However, the prevalence of HAND has also increased, especially the mild-to-moderate neurological dysfunction form. HAND is possibly caused by HIV-1 viral proteins resulting in CNS toxicity. The onset and progression of the neurological disorder vary with the age of patients and the different subtype of HIV-1 virus. Recent discoveries have demonstrated how different subtypes result in different through the viral proteins specific structures and sequences and results in different incidence and severity of HAND. More studies are required to understand better the mechanisms of how viral proteins cause HAND, as well as to explore the similarities and differences between different subtypes and degree of HAND. In addition, more research should be done to better identify the differences between HAND and neurodegenerative and neuropsychiatric diseases not caused by HIV infections. Equal importance should be given to the development of appropriate treatments for HAND, either with improved regimens or neuroprotective and psychostimulant compounds or novel specific therapies for HAND.

Acknowledgments

Supported by NIH grants (R01-NS059327; R01-NS076401, R01-MH093331, and R01-AG054411) awarded to BES.

References

1. Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. *PLoS Pathog.* 2014;10:e1004078. [PubMed: 24831517]
2. Hsue P, Shreay S, Song X, Meyer N. A Longitudinal Analysis of Comorbidities among Human Immunodeficiency Virus (HIV) Patients and Matched Non-HIV Controls in the USA. *ID Week*, New Orleans, Abstract 950; 2016.
3. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. *J Antimicrob Chemother.* 2003;51:229–40. [PubMed: 12562686]
4. Kuritzkes DR. HIV-1 subtype as a determinant of disease progression. *J Infect Dis.* 2008;197:638–9. [PubMed: 18266606]
5. McRae M. HIV and viral protein effects on the blood brain barrier. *Tissue Barriers.* 2016;4:e1143543. [PubMed: 27141423]
6. Bachani M, Sacktor N, McArthur JC, Nath A, Rumbaugh J. Detection of anti-tat antibodies in CSF of individuals with HIV-associated neurocognitive disorders. *J Neurovirol.* 2013;19:82–8. [PubMed: 23329164]
7. Giunta B, Hou H, Zhu Y, Rrapo E, Tian J, Takashi M, et al. HIV-1 tat contributes to Alzheimer's disease-like pathology in PSAPP mice. *Int J Clin Exp Pathol.* 2009;2:433–43. [PubMed: 19294002]
8. Nookala AR, Shah A, Noel RJ, Kumar A. HIV-1 tat-mediated induction of CCL5 in astrocytes involves NF- κ B, AP-1, C/EBP α and C/EBP γ transcription factors and JAK, PI3K/Akt and p38 MAPK signaling pathways. *PLoS One.* 2013;8:e78855. [PubMed: 24244375]
9. Ru W, Tang SJ. HIV-associated synaptic degeneration. *Mol Brain.* 2017;10:40. [PubMed: 28851400]

10. Hui L, Chen X, Haughey NJ, Geiger JD. Role of endolysosomes in HIV-1 tat-induced neurotoxicity. *ASN Neuro*. 2012;4:243–52. [PubMed: 22591512]
11. Eletto D, Russo G, Passiatore G, Del Valle L, Giordano A, Khalili K, et al. Inhibition of SNAP25 expression by HIV-1 tat involves the activity of mir-128a. *J Cell Physiol*. 2008;216:764–70. [PubMed: 18381601]
12. González ME. The HIV-1 vpr protein: a multifaceted target for therapeutic intervention. *Int J Mol Sci*. 2017;18:E126. [PubMed: 28075409]
13. Piller SC, Ewart GD, Jans DA, Gage PW, Cox GB. The amino-terminal region of vpr from human immunodeficiency virus Type 1 forms ion channels and kills neurons. *J Virol*. 1999;73:4230–8. [PubMed: 10196319]
14. Godet AN, Guernon J, Croset A, Cayla X, Falanga PB, Colle JH, et al. PP2A1 binding, cell transducing and apoptotic properties of vpr(77–92): a new functional domain of HIV-1 vpr proteins. *PLoS One*. 2010;5:e13760. [PubMed: 21072166]
15. Leymarie O, Lepont L, Berlioz-Torrent C. Canonical and non-canonical autophagy in HIV-1 replication cycle. *Viruses*. 2017;9:E270. [PubMed: 28946621]
16. Cheng X, Mukhtar M, Acheampong EA, Srinivasan A, Rafi M, Pomerantz RJ, et al. HIV-1 vpr potently induces programmed cell death in the CNS in vivo. *DNA Cell Biol*. 2007;26:116–31. [PubMed: 17328670]
17. Thaney VE, Sanchez AB, Fields JA, Minassian A, Young JW, Maung R, et al. Transgenic mice expressing HIV-1 envelope protein gp120 in the brain as an animal model in neuro AIDS research. *J Neurovirol*. 2018;24:156–67. [PubMed: 29075998]
18. Capó-Vélez CM, Delgado-Vélez M, Báez-Pagán CA, Lasalde-Dominicci JA. Nicotinic acetylcholine receptors in HIV: possible roles during HAND and inflammation. *Cell Mol Neurobiol*. 2018;38:1335–48. [PubMed: 30008143]
19. Hayasaka H, Kobayashi D, Yoshimura H, Nakayama EE, Shioda T, Miyasaka M, et al. The HIV-1 gp120/CXCR4 axis promotes CCR7 ligand-dependent CD4 T cell migration: CCR7 homo- and CCR7/CXCR4 hetero-oligomer formation as a possible mechanism for up-regulation of functional CCR7. *PLoS One*. 2015;10:e0117454. [PubMed: 25688986]
20. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. *Annu Rev Immunol*. 1999;17:657–700. [PubMed: 10358771]
21. Royal W 3rd, Zhang L, Guo M, Jones O, Davis H, Bryant JL, et al. Immune activation, viral gene product expression and neurotoxicity in the HIV-1 transgenic rat. *J Neuroimmunol*. 2012;247:16–24. [PubMed: 22503372]
22. Pandhare J, Dash S, Jones B, Villalta F, Dash C. A novel role of proline oxidase in HIV-1 envelope glycoprotein-induced neuronal autophagy. *J Biol Chem*. 2015;290:25439–51. [PubMed: 26330555]
23. Bachis A, Avdoshina V, Zecca L, Parsadanian M, Mocchetti I. Human immunodeficiency virus Type 1 alters brain-derived neurotrophic factor processing in neurons. *J Neurosci*. 2012;32:9477–84. [PubMed: 22787033]
24. Capó-Vélez CM, Morales-Vargas B, García-González A, Grajales-Reyes JG, Delgado-Vélez M, Madera B, et al. The alpha7-nicotinic receptor contributes to gp120-induced neurotoxicity: implications in HIV-associated neurocognitive disorders. *Sci Rep*. 2018;8:1829. [PubMed: 29379089]
25. Thaney VE, Kaul M. Type I interferons in neuroHIV. *Viral Immunol*. 2019;32:7–14. [PubMed: 30260742]
26. Liu J, Xu C, Chen L, Xu P, Xiong H. Involvement of kv1.3 and p38 MAPK signaling in HIV-1 glycoprotein 120-induced microglia neurotoxicity. *Cell Death Dis*. 2012;3:e254. [PubMed: 22258405]
27. Zou S, El-Hage N, Podhaizer EM, Knapp PE, Hauser KF. PTEN gene silencing prevents HIV-1 gp120(IIIB)-induced degeneration of striatal neurons. *J Neurovirol*. 2011;17:41–9. [PubMed: 21234828]
28. Singh IN, El-Hage N, Campbell ME, Lutz SE, Knapp PE, Nath A, et al. Differential involvement of p38 and JNK MAP kinases in HIV-1 tat and gp120-induced apoptosis and neurite degeneration in striatal neurons. *Neuroscience*. 2005;135:781–90. [PubMed: 16111829]

29. Torres-Muñoz J, Stockton P, Tacoronte N, Roberts B, Maronpot RR, Petito CK, et al. Detection of HIV-1 gene sequences in hippocampal neurons isolated from postmortem AIDS brains by laser capture micro-dissection. *J Neuropathol Exp Neurol*. 2001;60:885–92. [PubMed: 11556545]
30. Bagasra O, Lavi E, Bobroski L, Khalili K, Pestaner JP, Tawadros R, et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of *in situ* polymerase chain reaction and immunohistochemistry. *AIDS*. 1996;10:573–85. [PubMed: 8780811]
31. Hayashi N, Matsubara M, Jinbo Y, Titani K, Izumi Y, Matsushima N, et al. Nef of HIV-1 interacts directly with calcium-bound calmodulin. *Protein Sci*. 2002;11:529–37. [PubMed: 11847276]
32. Mangino G, Famiglietti M, Capone C, Veroni C, Percario ZA, Leone S, et al. HIV-1 myristoylated nef treatment of murine microglial cells activates inducible nitric oxide synthase, NO₂ production and neurotoxic activity. *PLoS One*. 2015;10:e0130189. [PubMed: 26066624]
33. Saribas AS, Cicalese S, Ahooyi TM, Khalili K, Amini S, Sariyer IK, et al. HIV-1 nef is released in extracellular vesicles derived from astrocytes: evidence for nef-mediated neurotoxicity. *Cell Death Dis*. 2017;8:e2542. [PubMed: 28079886]
34. Chompre G, Cruz E, Maldonado L, Rivera-Amill V, Porter JT, Noel RJ Jr., et al. Astrocytic expression of HIV-1 nef impairs spatial and recognition memory. *Neurobiol Dis*. 2013;49:128–36. [PubMed: 22926191]
35. Ruiseñor-Escudero H, Sikorskii A, Familiar-Lopez I, Persaud D, Ziemniak C, Nakasujja N, et al. Neurodevelopmental outcomes in pre-school children living with HIV-1 subtypes A and D in uganda. *Pediatr Infect Dis J*. 2018;37:e298–303. [PubMed: 29746376]
36. Santos da Silva E, Mulinge M, Lemaire M, Masquelier C, Beraud C, Rybicki A, et al. The envelope cytoplasmic tail of HIV-1 subtype C contributes to poor replication capacity through low viral infectivity and cell-to-cell transmission. *PLoS One*. 2016;11:e0161596. [PubMed: 27598717]
37. Kim S, Hahn YK, Podhaizer EM, McLane VD, Zou S, Hauser KF, et al. A central role for glial CCR5 in directing the neuropathological interactions of HIV-1 tat and opiates. *J Neuroinflammation*. 2018;15:285. [PubMed: 30305110]
38. Ranga U, Shankarappa R, Siddappa NB, Ramakrishna L, Nagendran R, Mahalingam M, et al. Tat protein of human immunodeficiency virus Type 1 subtype C strains is a defective chemokine. *J Virol*. 2004;78:2586–90. [PubMed: 14963162]
39. Rao VR, Sas AR, Eugenin EA, Siddappa NB, Bimonte-Nelson H, Berman JW, et al. HIV-1 clade-specific differences in the induction of neuropathogenesis. *J Neurosci*. 2008;28:10010–6. [PubMed: 18829958]
40. Campbell GR, Watkins JD, Loret EP, Spector SA. Differential induction of rat neuronal excitotoxic cell death by human immunodeficiency virus Type 1 clade B and C tat proteins. *AIDS Res Hum Retroviruses*. 2011;27:647–54. [PubMed: 20977378]
41. Aralaguppe SP, Sharma S, Menon M, Prasad VR, Saravanan S, Murugavel KG, et al. The evolving profile of the signature amino acid residues in HIV-1 subtype C tat. *AIDS Res Hum Retroviruses*. 2016;32:503–14. [PubMed: 26678403]
42. Aksenov MY, Aksenova MV, Mactutus CF, Booze RM. HIV-1 protein-mediated amyloidogenesis in rat hippocampal cell cultures. *Neurosci Lett*. 2010;475:174–8. [PubMed: 20363291]
43. Li W, Huang Y, Reid R, Steiner J, Malpica-Llanos T, Darden TA, et al. NMDA receptor activation by HIV-tat protein is clade dependent. *J Neurosci*. 2008;28:12190–8. [PubMed: 19020013]
44. Samikkannu T, Agudelo M, Gandhi N, Reddy PV, Saiyed ZM, Nwankwo D, et al. Human immunodeficiency virus Type 1 clade B and C gp120 differentially induce neurotoxin arachidonic acid in human astrocytes: implications for neuroAIDS. *J Neurovirol*. 2011;17:230–8. [PubMed: 21491143]
45. Donnelly MR, Ciborowski P. Proteomics, biomarkers, and HIV-1: a current perspective. *Proteomics Clin Appl*. 2016;10:110–25. [PubMed: 26033875]
46. Na H, Acharjee S, Jones G, Vivithanaporn P, Noorbakhsh F, McFarlane N, et al. Interactions between human immunodeficiency virus (HIV)-1 vpr expression and innate immunity influence neurovirulence. *Retrovirology*. 2011;8:44. [PubMed: 21645334]
47. Lamers SL, Fogel GB, Liu ES, Barbier AE, Rodriguez CW, Singer EJ, et al. Brain-specific HIV nef identified in multiple patients with neurological disease. *J Neurovirol*. 2018;24:1–5.

48. Brunetti A, Berg G, Di Chiro G, Cohen RM, Yarchoan R, Pizzo PA, et al. Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study. *J Nucl Med*. 1989;30:581–90. [PubMed: 2785582]
49. Baldeweg T, Catalan J, Gazzard BG. Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy. *J Neurol Neurosurg Psychiatry*. 1998;65:34–41. [PubMed: 9667558]
50. Chiesi A, Agresti MG, Dally LG, Zaccarelli M, Tomino C, Floridia M, et al. Decrease in notifications of AIDS dementia complex in 1989–1990 in Italy: possible role of the early treatment with zidovudine. *Medicina (Firenze)*. 1990;10:415–6. [PubMed: 2099987]
51. Eggers C, Arendt G, Hahn K, Husstedt IW, Maschke M, Neuen-Jacob E, et al. HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. *J Neurol*. 2017;264:1715–27. [PubMed: 28567537]
52. Sánchez-Portocarrero J, Jiménez-Escrig A, Pérez-Cecilia E, Ayuso-Mateos JL, Roca V, Yague MR, et al. AIDS dementia complex: incidence, clinical profile and impact of zidovudine treatment. *Eur J Neurol*. 1996;3:191–7. [PubMed: 21284769]
53. Del Palacio M, Alvarez S, Muñoz-Fernández MÁ. HIV-1 infection and neurocognitive impairment in the current era. *Rev Med Virol*. 2012; 22:33–45. [PubMed: 21990255]
54. Sacktor NC, Skolasky RL, Lyles RH, Esposito D, Selnes OA, McArthur JC, et al. Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. *J Neurovirol*. 2000;6:84–8. [PubMed: 10787000]
55. De Almeida TB, de Azevedo MC, Pinto JF, Ferry FR, da Silva GA, de Castro IJ, et al. Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. *J Antimicrob Chemother*. 2018;73:2460–7. [PubMed: 29868865]
56. Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. *Neurology*. 2011; 76:1403–9. [PubMed: 21502598]
57. Raines C, Radcliffe O, Treisman GJ. Neurologic and psychiatric complications of antiretroviral agents. *J Assoc Nurses AIDS Care*. 2005; 16:35–48. [PubMed: 16433108]
58. Lan X, Kiyota T, Hanamsagar R, Huang Y, Andrews S, Peng H, et al. The effect of HIV protease inhibitors on amyloid- β peptide degradation and synthesis in human cells and Alzheimer's disease animal model. *J Neuroimmune Pharmacol*. 2012;7:412–23. [PubMed: 21826404]
59. Sharma B, Singh N, Singh M, Jaggi AS. Exploitation of HIV protease inhibitor indinavir as a memory restorative agent in experimental dementia. *Pharmacol Biochem Behav*. 2008;89:535–45. [PubMed: 18343489]
60. Perloff MD, von Moltke LL, Fahey JM, Greenblatt DJ. Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. *J Pharm Pharmacol*. 2007;59:947–53. [PubMed: 17637189]
61. Kaddoumi A, Choi SU, Kinman L, Whittington D, Tsai CC, Ho RJ, et al. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. *Drug Metab Dispos*. 2007;35:1459–62. [PubMed: 17591677]
62. Yilmaz A, Price RW, Gisslén M. Antiretroviral drug treatment of CNS HIV-1 infection. *J Antimicrob Chemother*. 2012;67:299–311. [PubMed: 22160207]
63. Das MK, Sarma A, Chakraborty T. Nano-ART and neuroAIDS. *Drug Deliv Transl Res*. 2016;6:452–72. [PubMed: 27137528]
64. Nair M, Jayant RD, Kaushik A, Sagar V. Getting into the brain: potential of nanotechnology in the management of neuroAIDS. *Adv Drug Deliv Rev*. 2016;103:202–17. [PubMed: 26944096]
65. Ene L, Duiculescu D, Ruta SM. How much do antiretroviral drugs penetrate into the central nervous system? *J Med Life*. 2011;4:432–9. [PubMed: 22514580]
66. Doyle T, Dunn DT, Ceccherini-Silberstein F, De Mendoza C, Garcia F, Smit E, et al. Integrase inhibitor (INI) genotypic resistance in treatment-naïve and raltegravir-experienced patients infected with diverse HIV-1 clades. *J Antimicrob Chemother*. 2015;70:3080–6. [PubMed: 26311843]

67. Bar-Magen T, Sloan RD, Faltenbacher VH, Donahue DA, Kuhl BD, Oliveira M, et al. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. *Retrovirology*. 2009;6:103. [PubMed: 19906306]
68. Antinori A, Zaccarelli M, Cingolani A, Forbici F, Rizzo MG, Trotta MP, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. *AIDS Res Hum Retroviruses*. 2002;18:835–8. [PubMed: 12201905]
69. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. *Science*. 1992;256:1783–90. [PubMed: 1377403]
70. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. *Science*. 1995;267:988–93. [PubMed: 7532321]
71. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. *Nat Struct Biol*. 1995;2:293–302. [PubMed: 7540934]
72. Das K, Arnold E. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. *Curr Opin Virol*. 2013;3:111–8. [PubMed: 23602471]
73. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. *AIDS*. 2003;17:F1–5. [PubMed: 12478089]
74. Grossman Z, Istomin V, Averbuch D, Lorber M, Risenberg K, Levi I, et al. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. *AIDS*. 2004;18:909–15. [PubMed: 15060438]
75. Reuman EC, Rhee SY, Holmes SP, Shafer RW. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. *J Antimicrob Chemother*. 2010;65:1477–85. [PubMed: 20462946]
76. Rhee SY, Kantor R, Katzenstein DA, Camacho R, Morris L, Sirivichayakul S, et al. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. *AIDS*. 2006;20:643–51. [PubMed: 16514293]
77. Basson AE, Rhee SY, Parry CM, El-Khatib Z, Charalambous S, De Oliveira T, et al. Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors. *Antimicrob Agents Chemother*. 2015;59:960–71. [PubMed: 25421485]
78. Sluis-Cremer N, Jordan MR, Huber K, Wallis CL, Bertagnolio S, Mellors JW, et al. E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings. *Antiviral Res*. 2014;107:31–4. [PubMed: 24746459]
79. Shin AH, Kim HJ, Thayer SA. Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 tat. *Br J Pharmacol*. 2012;166:1002–17. [PubMed: 22142193]
80. Adams SM, Aksenova MV, Aksenov MY, Mactutus CF, Booze RM. ER- β mediates 17 β -estradiol attenuation of HIV-1 tat-induced apoptotic signaling. *Synapse*. 2010;64:829–38. [PubMed: 20340172]
81. Paris JJ, Zou S, Hahn YK, Knapp PE, Hauser KF 5 α -reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 tat. *Brain Behav Immun*. 2016;55:202–14. [PubMed: 26774528]
82. Corasaniti MT, Amantea D, Russo R, Piccirilli S, Leta A, Corazzari M, et al. 17 β -estradiol reduces neuronal apoptosis induced by HIV-1 gp120 in the neocortex of rat. *Neurotoxicology*. 2005;26:893–903. [PubMed: 15922453]
83. Russo R, Navarra M, Maiuolo J, Rotiroti D, Bagetta G, Corasaniti MT. 17 β -estradiol protects SH-SY5Y cells against HIV-1 gp120-induced cell death: evidence for a role of estrogen receptors. *NeuroToxicology*. 2005;26:905–13. [PubMed: 15899520]
84. McLaurin KA, Li H, Booze RM, Fairchild AJ, Mactutus CF. Unraveling individual differences in the HIV-1 transgenic rat: therapeutic efficacy of methylphenidate. *Sci Rep*. 2018;8:136. [PubMed: 29317696]

85. Frain JA, Chen L. Examining the effectiveness of a cognitive intervention to improve cognitive function in a population of older adults living with HIV: a pilot study. *Ther Adv Infect Dis*. 2018;5:19–28. [PubMed: 29344357]
86. Prommer E Methylphenidate: established and expanding roles in symptom management. *Am J Hosp Palliat Care*. 2012;29:483–90. [PubMed: 22144657]
87. Veenhuis RT, Clements JE, Gama L. HIV eradication strategies: implications for the central nervous system. *Curr HIV/AIDS Rep*. 2019;16:96–104. [PubMed: 30734905]

Figure 1. Summary of HIV-1 proteins' contribution to the progression of HIV-associated neurocognitive disorder (HAND). The contribution of HIV-1 Tat, Vpr, gp120, and Nef to neuronal apoptosis and HAND.

Figure 2.

Comparison of subtype B to subtype C. A comparison of HIV-1 subtype B and subtype C elements and their contribution to the severity and incidence of HIV-associated neurocognitive disorder.